PepGen (NASDAQ:PEPG - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $26.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 424.19% from the stock's current price.
Other equities research analysts have also recently issued reports about the company. Wedbush restated an "outperform" rating and set a $20.00 price objective on shares of PepGen in a research note on Wednesday, July 31st. Bank of America cut shares of PepGen from a "buy" rating to a "neutral" rating and set a $12.00 target price for the company. in a research note on Wednesday, July 31st.
Read Our Latest Report on PepGen
PepGen Price Performance
PEPG stock traded down $0.67 during mid-day trading on Friday, reaching $4.96. The company had a trading volume of 166,032 shares, compared to its average volume of 39,668. PepGen has a 12 month low of $3.72 and a 12 month high of $19.30. The firm has a 50 day moving average of $8.58 and a 200 day moving average of $12.26.
PepGen (NASDAQ:PEPG - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.15). As a group, equities analysts anticipate that PepGen will post -3.16 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new position in PepGen during the 1st quarter worth approximately $30,000. Point72 DIFC Ltd purchased a new position in shares of PepGen during the second quarter worth $42,000. Allspring Global Investments Holdings LLC purchased a new position in shares of PepGen during the 3rd quarter valued at about $95,000. Renaissance Technologies LLC acquired a new position in shares of PepGen in the 2nd quarter valued at about $192,000. Finally, Marshall Wace LLP purchased a new stake in shares of PepGen in the second quarter worth about $196,000. 58.01% of the stock is currently owned by hedge funds and other institutional investors.
About PepGen
(
Get Free Report)
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Recommended Stories
Before you consider PepGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PepGen wasn't on the list.
While PepGen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
